HUP0202259A2 - Szabályozott hatóanyag-leadású gyógyszer dózisforma, mely legalább egy időzített hatóanyag-leadást biztosít - Google Patents

Szabályozott hatóanyag-leadású gyógyszer dózisforma, mely legalább egy időzített hatóanyag-leadást biztosít

Info

Publication number
HUP0202259A2
HUP0202259A2 HU0202259A HUP0202259A HUP0202259A2 HU P0202259 A2 HUP0202259 A2 HU P0202259A2 HU 0202259 A HU0202259 A HU 0202259A HU P0202259 A HUP0202259 A HU P0202259A HU P0202259 A2 HUP0202259 A2 HU P0202259A2
Authority
HU
Hungary
Prior art keywords
dosage forms
pharmaceutical dosage
controlled release
timed pulse
release producing
Prior art date
Application number
HU0202259A
Other languages
English (en)
Inventor
Frédéric Andre
Gareth Lewis
Jérome Mignonneau
Agnés Ribardiere
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of HUP0202259A2 publication Critical patent/HUP0202259A2/hu
Publication of HUP0202259A3 publication Critical patent/HUP0202259A3/hu
Publication of HU229312B1 publication Critical patent/HU229312B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány késleltetett hatóanyag-leadású bevont magokra, amelyek egyhatóanyagot tartalmazó magból és egy, legalább egy vagy több ammonio-metakrilát kopolimert tartalmazó polimerbevonatból állnak, amelyekrejellemző, hogy a mag legalább egy felületaktív anyagot foglal magában,monolit vagy több részből álló gyógyszer-dózisformákra, amelyek ilyenkésleltetett hatóanyag-leadású bevont magokat tartalmaznak, és ezekelőállítására alkalmas eljárásra vonatkozik. Ó
HU0202259A 1999-06-28 2000-06-27 Szabályozott hatóanyag-leadású gyógyszer-dózisformák legalább egy idõzített gyors szakaszt magába foglaló szabályozott hatóanyag-leadásra HU229312B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99401606A EP1064938A1 (en) 1999-06-28 1999-06-28 Pharmaceutical dosage forms for controlled release producing at least a timed pulse
PCT/EP2000/006795 WO2001000182A1 (en) 1999-06-28 2000-06-27 Pharmaceutical dosage forms for controlled release producing at least a timed pulse

Publications (3)

Publication Number Publication Date
HUP0202259A2 true HUP0202259A2 (hu) 2002-12-28
HUP0202259A3 HUP0202259A3 (en) 2004-05-28
HU229312B1 HU229312B1 (hu) 2013-10-28

Family

ID=8242029

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202259A HU229312B1 (hu) 1999-06-28 2000-06-27 Szabályozott hatóanyag-leadású gyógyszer-dózisformák legalább egy idõzített gyors szakaszt magába foglaló szabályozott hatóanyag-leadásra

Country Status (29)

Country Link
US (1) US20080175910A1 (hu)
EP (2) EP1064938A1 (hu)
JP (1) JP2003503341A (hu)
KR (1) KR100794402B1 (hu)
CN (2) CN1358088A (hu)
AR (1) AR024492A1 (hu)
AT (1) ATE274902T1 (hu)
AU (1) AU780769B2 (hu)
BR (1) BR0011999A (hu)
CA (1) CA2370067C (hu)
CO (1) CO5190681A1 (hu)
CZ (1) CZ296067B6 (hu)
DE (1) DE60013445T2 (hu)
DK (1) DK1194131T3 (hu)
ES (1) ES2225183T3 (hu)
HK (1) HK1043056B (hu)
HU (1) HU229312B1 (hu)
IL (2) IL146768A0 (hu)
MX (1) MXPA01013408A (hu)
NO (1) NO332952B1 (hu)
NZ (1) NZ515826A (hu)
PL (1) PL200816B1 (hu)
PT (1) PT1194131E (hu)
SI (1) SI1194131T1 (hu)
SK (1) SK285359B6 (hu)
TR (1) TR200103604T2 (hu)
TW (1) TWI242451B (hu)
WO (1) WO2001000182A1 (hu)
ZA (1) ZA200109849B (hu)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5005157B2 (ja) 2001-03-13 2012-08-22 ペンウェスト ファーマシューティカルズ カンパニー 時間治療（ｃｈｒｏｎｏｔｈｅｒａｐｅｕｔｉｃ）投与形態
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
RU2311903C2 (ru) * 2001-11-07 2007-12-10 Синтон Б.В. Таблетки тамзулосина
DE60218885T2 (de) * 2001-11-30 2008-01-17 Pfizer Products Inc., Groton Orale pharmazeutische Arzneiformen bzw. Dosierungsformen von 5,8,14-Triazatetra-cyclo-(10.3.1.0 (2,11).0(4,9)-hexadeca-2(11),3,5,7,9-pentaen mit kontrollierter Freisetzung
WO2003051339A1 (fr) * 2001-12-19 2003-06-26 Sanwa Kagaku Kenkyusho Co.,Ltd Produit façonne du type a liberation controlee
AU2003244840C1 (en) * 2002-07-05 2010-03-04 Temrel Limited Controlled release composition
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
MXPA05004338A (es) * 2002-10-22 2005-06-22 Ranbaxy Lab Ltd Composiciones de liberacion sostenida que contienen alfuzosin.
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
KR100592512B1 (ko) * 2002-11-22 2006-07-03 서울약품공업(주) 탐술로신 또는 약제학적으로 허용되는 이의 염을활성성분으로 하는 서방성 배뇨장애 치료제
IN192381B (hu) * 2002-12-20 2004-04-10 Ranbaxy Lab
MXPA06003101A (es) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
WO2005027878A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Delayed released dosage forms
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
KR100436701B1 (ko) * 2003-11-07 2004-06-22 주식회사 씨티씨바이오 염산 탐스로신 함유 방출 조절형 제제 및 그의 제조방법
US8292729B2 (en) 2003-12-02 2012-10-23 United Tote Company Methods and systems for presenting pari-mutuel betting options and constructing wagers
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
KR20070087678A (ko) * 2004-12-20 2007-08-28 컬리지움 파마슈티칼, 인코포레이티드 수면 장애용 약제 조성물
MX2007008985A (es) * 2005-01-26 2007-12-06 Elan Pharma Int Ltd Composiciones de liberacion controlada que comprenden un agente anti-sicotico.
CN101111231A (zh) * 2005-03-29 2008-01-23 罗姆有限公司 包含具有影响调节物质递送的基质的小丸的多颗粒药用形式
US8206742B2 (en) 2006-01-12 2012-06-26 Wockhardt Ltd. Sustained release compositions of alfuzosin
US20070292505A1 (en) * 2006-06-15 2007-12-20 Abrika Pharmaceuticals, Inc. Controlled release alfuzosin hydrochloride formulation
US20080095844A1 (en) * 2006-10-23 2008-04-24 Rajhans Sujay Kamalakar Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
CN101269056B (zh) * 2007-03-19 2010-05-19 天津药物研究院 一种美托洛尔盐类口服脉冲微丸制剂
US8178483B2 (en) * 2007-03-30 2012-05-15 Colgate-Palmolive Company Polymeric encapsulates having a quaternary ammonium salt and methods for producing the same
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
FR2928929B1 (fr) * 2008-03-19 2012-01-13 Saint Gobain Composition serigraphiable sur polyvinylbutyral
CN102548544B (zh) * 2009-10-09 2015-01-21 永进药品工业株式会社 同时具有速效特性和长效特性的药物组合物
CN102106841B (zh) * 2009-12-24 2013-01-09 杭州康恩贝制药有限公司 一种盐酸坦洛新制剂及其制备方法
PL2552418T3 (pl) 2010-03-29 2017-12-29 Ferring B.V. Szybko rozpuszczająca się kompozycja farmaceutyczna
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
KR101686033B1 (ko) * 2010-04-12 2016-12-13 주식회사 대웅제약 탐술로신 또는 이의 약제학적 허용 가능한 염을 유효성분으로 함유하는 장용성 서방형 펠렛부와 속방부로 이루어진 의약 조성물
WO2011144994A1 (en) * 2010-05-21 2011-11-24 Lupin Limited Pharmaceutical compositions of nsaid and acid inhibitor
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
EP3370518B1 (en) 2015-10-14 2023-08-23 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
CN105362233A (zh) * 2015-12-07 2016-03-02 黑龙江省智诚医药科技有限公司 一种卡托普利缓释微丸及其制备方法
EP3777842A1 (en) * 2016-10-31 2021-02-17 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
US10278930B2 (en) 2017-03-16 2019-05-07 The Procter & Gamble Company Method for relieving sinus congestion
CN107233328A (zh) * 2017-06-13 2017-10-10 江苏黄河药业股份有限公司 卡托普利缓释片剂及其制备方法
CN107362161B (zh) * 2017-08-14 2020-05-29 黄河科技学院 一种复方卡托普利硝苯地平脉冲缓释制剂及其制备方法
TR201721036A2 (tr) 2017-12-21 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Flurbi̇profeni̇n modi̇fi̇ye salimli formülasyonlari
JP7162330B2 (ja) * 2018-07-11 2022-10-28 株式会社アタゴ 粘度計
CN110075090A (zh) * 2019-05-17 2019-08-02 南京望知星医药科技有限公司 一种用于治疗呼吸疾病的沙丁胺醇胶囊及其制备方法
CN110037994B (zh) * 2019-05-24 2022-04-12 中国药科大学 一种布洛芬速释缓释双层片及其制备方法
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA822995B (en) * 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4677099A (en) * 1981-09-04 1987-06-30 Yeda Research And Development Co., Ltd. Medical processes employing a novel lipid fraction
US4370313A (en) * 1981-10-26 1983-01-25 Eaton Laboratories, Inc. Nitrofurantoin dosage form
JPS58116414A (ja) * 1981-12-23 1983-07-11 Yamanouchi Pharmaceut Co Ltd ニカルジピン持続性製剤用球形顆粒およびその製造法
US4614796A (en) * 1983-03-25 1986-09-30 Nippon Shinyaku Co., Ltd. Liposome and method of manufacture therefor
DE3678643D1 (de) * 1985-08-16 1991-05-16 Procter & Gamble Partikel mit konstanter wirkstofffreisetzung.
US4986987A (en) * 1986-05-09 1991-01-22 Alza Corporation Pulsed drug delivery
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
ES2077023T3 (es) * 1989-03-10 1995-11-16 Yamanouchi Pharma Co Ltd Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada.
US5176901A (en) * 1991-04-10 1993-01-05 Smithkline Beecham Corporation Dental composition
EP0546593B1 (en) * 1991-10-30 1997-09-03 Glaxo Group Limited Multi-layered compositions containing histamine or serotonin antagonists
CA2122479C (en) * 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
CA2150119C (en) * 1992-11-30 2005-03-15 Robert C. Cuca Tastemasked pharmaceutical materials
WO1995003052A1 (en) * 1993-07-22 1995-02-02 Warner-Lambert Company Controlled release tacrine drug delivery systems and methods for preparing same
FR2717388B1 (fr) * 1994-03-21 1996-11-22 Synthelabo Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
FR2742660B1 (fr) * 1995-12-22 1998-04-03 Ethypharm Lab Prod Ethiques Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
US6020375A (en) * 1997-06-13 2000-02-01 Senju Pharmaceutical Co., Ltd. Bactericidal composition
BR9802915A (pt) * 1997-09-12 2000-01-11 Oscar Gold Procedimento para formar composições farmaceuticas em pilulas ou granulos substancialmente esfericos, de ação controlada e continuada, contendo como agente ativo o (7-bromo-1,3-diidro-5-(2-piridninilo)-2h-1,4-benzodiazep ina-2(1h)-um)
US5922341A (en) * 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
DK173431B1 (da) * 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
US6124362A (en) * 1998-07-17 2000-09-26 The Procter & Gamble Company Method for regulating hair growth
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6495498B2 (en) * 1999-05-27 2002-12-17 Johnson & Johnson Consumer Companies, Inc. Detergent compositions with enhanced depositing, conditioning and softness capabilities

Also Published As

Publication number Publication date
DE60013445D1 (de) 2004-10-07
CZ20014639A3 (cs) 2002-04-17
ES2225183T3 (es) 2005-03-16
HUP0202259A3 (en) 2004-05-28
SK19102001A3 (sk) 2002-05-09
ZA200109849B (en) 2003-02-26
AU6274700A (en) 2001-01-31
IL146768A (en) 2010-05-17
AR024492A1 (es) 2002-10-02
AU780769B2 (en) 2005-04-14
CN1358088A (zh) 2002-07-10
DK1194131T3 (da) 2005-01-17
HU229312B1 (hu) 2013-10-28
PT1194131E (pt) 2005-01-31
CN101669914A (zh) 2010-03-17
PL354399A1 (en) 2004-01-12
NZ515826A (en) 2004-04-30
MXPA01013408A (es) 2002-07-30
HK1043056B (zh) 2005-04-29
CO5190681A1 (es) 2002-08-29
EP1194131A1 (en) 2002-04-10
CA2370067C (en) 2009-07-28
NO20016282L (no) 2002-02-27
CZ296067B6 (cs) 2006-01-11
SI1194131T1 (en) 2005-04-30
WO2001000182A1 (en) 2001-01-04
BR0011999A (pt) 2002-03-05
ATE274902T1 (de) 2004-09-15
US20080175910A1 (en) 2008-07-24
IL146768A0 (en) 2002-07-25
CA2370067A1 (en) 2001-01-04
TR200103604T2 (tr) 2002-04-22
EP1064938A1 (en) 2001-01-03
SK285359B6 (sk) 2006-11-03
KR100794402B1 (ko) 2008-01-16
PL200816B1 (pl) 2009-02-27
HK1043056A1 (en) 2002-09-06
NO332952B1 (no) 2013-02-11
TWI242451B (en) 2005-11-01
EP1194131B1 (en) 2004-09-01
KR20020015065A (ko) 2002-02-27
DE60013445T2 (de) 2005-09-01
NO20016282D0 (no) 2001-12-20
JP2003503341A (ja) 2003-01-28

Similar Documents

Publication Publication Date Title
HUP0202259A2 (hu) Szabályozott hatóanyag-leadású gyógyszer dózisforma, mely legalább egy időzített hatóanyag-leadást biztosít
PL356962A1 (en) Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
ES2180683T3 (es) Preparacion de nifedipina de liberacion con duracion prolongada.
WO2002002525A3 (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
FI93924B (fi) Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
BRPI0409652A (pt) tablete, embalagem farmacêutica, método de tratamento de doenças, e, método de preparação de um tablete
AU2002254036A1 (en) Taste masked pharmaceutical compositions
IT1289160B1 (it) Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
NO20031694L (no) Krystallinsk monohydrat, fremgangsmåte for fremstilling derav og anvendelsederav til fremstilling av et medikament
YU36700A (sh) Oralni farmaceutski oblik za doziranje sa produženim oslobađanjem
AU2001278771A1 (en) Carboxylic acid derivatives, process for producing the same and drugs containingthe same as the active ingredient
ES2036457A1 (es) Forma de dosificacion farmaceutica solida oral de liberacion programada y procedimiento de preparacion.
HUP9900337A2 (hu) Omega-3-Politelítetlen savak orális adagolási formái gyulladásos bélbetegségek kezelésére
WO2001098268A3 (en) Piperidine amides as modulators of chemokine receptor activity
ATE429903T1 (de) Pharmazeutische zubereitung mit verzögerter wirkstoff-freisetzung enthaltend milchsäure- glycolsäure copolymer, und verfahren zu deren herstellung
WO2003047529A3 (en) Extended release pharmaceutical tablet of metformin
AU1495595A (en) Sustained-release dosage forms of alfuzosin hydrochloride
DK0854879T3 (da) Nye forbindelser afledt af 5-0-desosamiyl-6-0-methyl-erythronolid A, fremgangsmåde til deres fremstilling og deres anvendelse til fremstilling af biologisk aktive stoffer
WO2005009410A3 (en) Pharmaceutical compositions having a swellable coating
WO2001098269A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
DK0755919T3 (da) Substituerede kanelsyreguanidider, fremgangsmåde til deres fremstilling, deres anvendelse som hjerte-kredsløbs-medikament e
ATE329589T1 (de) Multipartikuläre bisoprolol formulierung
MY139719A (en) Oral dosage form for controlled drug release
AU2001291695A1 (en) Method for the production of capsules containing active ingredients by miniemulsion polymerisation

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees